Executive Summary

1. Nanomedicine platform: engineered to transform oncology efficacy with dramatically reduced systemic toxicity.
2. ONX-1006: nanoparticle paclitaxel designed for repeated, sustained treatment, with no treatment-related adverse effects observed at the preclinical NOAEL.
3. Efficacy: modeling suggests 90–100% tumor elimination over one year, with a clinical goal of 70% one-year survival.
4. Scalable nanomedicine manufacturing: standardized process established with 15 kg successfully produced.

View or download the full Executive Summary below.

To learn more about Onselex or discuss an investment or strategic partnership opportunity, please contact us.

Company Video:
https://onselex.com/en/sub/sub04_01.php?boardid=newsen&mode=view&idx=7

Contact:
CureCancer@OnSelex.com